| Placebo group (n = 40) | CLE group (n = 39) | p value | ||
---|---|---|---|---|---|
 | Mean | SD | Mean | SD | |
SF-36 scores, points | |||||
 Physical functioning (PF) | 92.5 | 6.8 | 91.8 | 12.8 | 0.762 |
 Role physical (RP) | 94.7 | 10.2 | 93.1 | 13.4 | 0.558 |
 Bodily pain (BP) | 88.3 | 13.5 | 89.0 | 16.6 | 0.826 |
 General health (GH) | 71.7 | 13.9 | 77.6 | 13.9 | 0.060 |
 Vitality (VT) | 65.3 | 16.1 | 69.9 | 20.4 | 0.269 |
 Social functioning (SF) | 94.7 | 10.2 | 91.7 | 14.4 | 0.287 |
 Role emotional (RE) | 94.4 | 10.9 | 92.9 | 13.2 | 0.599 |
 Mental health (MH) | 80.1 | 12.2 | 79.4 | 15.4 | 0.812 |
 Physical component summary (PCS) | 53.4 | 4.4 | 52.2 | 7.0 | 0.382 |
 Mental component summary (MCS) | 56.5 | 5.9 | 58.0 | 8.8 | 0.358 |
POMS scores, points | |||||
 Anger-hostility (AH) | 45.5 | 6.9 | 45.4 | 6.2 | 0.979 |
 Confusion-bewilderment (CB) | 46.9 | 6.9 | 46.0 | 8.1 | 0.619 |
 Depression-dejection (DD) | 47.3 | 6.8 | 47.0 | 7.5 | 0.877 |
 Fatigue-inertia (FI) | 45.2 | 5.8 | 44.2 | 8.1 | 0.540 |
 Tension-anxiety (TA) | 48.7 | 8.9 | 45.9 | 7.8 | 0.142 |
 Vigor-activity (VA) | 54.4 | 9.1 | 56.3 | 9.2 | 0.362 |
 Friendliness (F) | 56.3 | 9.4 | 56.5 | 9.3 | 0.901 |
 Total mood disturbance (TMD) | 45.3 | 6.8 | 43.7 | 8.0 | 0.332 |